Catalyst
Slingshot members are tracking this event:
PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PFE | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ibrance, Palbociclib, Her2- Metastatic Breast Cancer, Paloma-2
